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Objective: We assessed whether individualized shortened duration of elastic compression stocking (ECS) therapy after
acute deep venous thrombosis (DVT) is feasible without increasing the incidence of postthrombotic syndrome (PTS).
Methods: At the outpatient clinic of the Maastricht University Medical Centre, 125 consecutive patients with confirmed
proximal DVT were followed for 2 years. Villalta scores were assessed on four consecutive visits; 3, 6, 12, and 24 months
after the acute event. Reflux was assessed once by duplex testing. After 6 months, patients with scores <4 on the Villalta
clinical score and in the absence of reflux were allowed to discontinue ECS therapy. If reflux was present, two consecutive
scores <4 were needed to discontinue ECS therapy.
Results: ECS therapy was discontinued in 17% of patients at 6 months, in 48% at 12 months, and in 50% at 24 months.
Reflux on duplex testing was present in 74/101 (73.3%) tested patients and was not associated with the onset of PTS. At
the 6-month visit, the cumulative incidence of PTS was 13.3%, at 12 months 17.0%, and at 24 months 21.1%.
Varicosities/venous insufficiency (present at baseline) was significantly associated with PTS; hazard ratio 3.2 (1.2-9.1).
Conclusions: Patients with a low probability for developing PTS can be identified as early as 6 months after the thrombotic
event, and individualized shortened duration of ECS therapy based on Villalta clinical scores may be a safe management
option. These findings need to be confirmed in a randomized clinical trial. ( J Vasc Surg 2010;52:132-8.)Postthrombotic syndrome (PTS) is a chronic condition
that arises in 20% to 50% of patients following deep venous
thrombosis (DVT) and is therefore considered to be the
most common complication of DVT.1-4
The quality of life is negatively affected by PTS, and
substantial healthcare costs are generated.5,6 Both the ob-
struction of limbs by residual thrombosis as well as the
presence of reflux in the femoral vein and popliteal vein
after an event of DVT are considered to be of importance
for the development of valvular incompetence and of post-
thrombotic complaints.7-10
The diagnosis of PTS is usually made when both clinical
symptoms indicative of PTS, as well as reflux, are present.
Nevertheless, patients may have valvular incompetence af-
ter DVT but, at the same time, do not suffer from PTS.11,12
The clinical diagnosis of PTS is based on clinical signs and
symptoms that are scored according to a clinical scale.13-15
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132Clinical manifestations of PTS are pain, edema, skin
changes, venous claudication, and, in severe cases, even
venous ulcers may occur. Elastic compression therapy has
been observed to reduce the incidence of PTS in unselected
patients by almost half.16 The evidence supporting the
value of compression therapy is derived from two random-
ized clinical studies only.16-17
These trials did not evaluate whether some patients
could benefit more from long-term duration of compres-
sion therapy than others. Therefore, the issue whether all
patients need to have compression therapy for a period of 2
years remains unclear. Compliance with therapy can be
demanding for all patients, but possibly even more so for
those patients who do not experience any complaints.
In a prospective management cohort study, we there-
fore assessed whether individualized duration of elastic
compression therapy, after initial compression therapy of 6
months following an acute event of DVT, had an impact on
the incidence of PTS. In addition, we evaluated whether
some of the known risk factors for PTS can help select
patients who can potentially benefit more from prolonged
compression therapy.
METHODS
Patients
Consecutive patients with confirmed acute proximal
DVT, defined as thrombosis in the popliteal vein (including
the trifurcation), the femoral vein, or the common femoral
vein, were followed for a period of 2 years after the acute
event as part of routine patient care at the outpatient clinic
of the Maastricht University Medical Centre, Maastricht,
the Netherlands, between July 2003 and December 2006.
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tion in the study; the only inclusion criterion was acute
objectively confirmed proximal DVT, and there were no
exclusion criteria.
Anticoagulant treatment was installed according to in-
ternational guidelines and individually tailored when nec-
essary.18 Patients were provided with compression ban-
dages within 24 hours of diagnosis, and no bed rest was
prescribed. The initial treatment consisted of therapeutic
doses of low molecular weight heparin (LMWH) for a
period of at least 5 days, together with vitamin K antago-
nists. LMWH was stopped after reaching an international
normalized ratio (INR) of two or higher on two consecutive
measurements. Treatment was supervised by the Thrombosis
Service Maastricht, an organization that closely monitors the
INR of patients on anticoagulant treatment. Patients with
provoked thrombosis were treated with anticoagulantmed-
ication for 3 months. In patients with a first event of
idiopathic thrombosis, initial anticoagulant therapy was
installed for a period of 6 months. All patients underwent
compression ultrasound testing to assess residual thrombo-
sis at 1 week before planned cessation of anticoagulant
therapy. Whenever residual thrombosis was found at com-
pression ultrasound examination, patients received ex-
tended anticoagulant therapy in order to reduce the risk of
recurrent thrombosis.19-21 Patients with previous events of
venous thromboembolism were treated for at least 12
months or indefinitely.
Baseline examination
At the screening visit, a thoroughmedical check-up was
performed, and a clinical history was taken. Risk factors
were assessed both for venous thromboembolism (VTE)
and for PTS. Risk factors for PTS included previous VTE,
presence of malignant disease, obesity, age over 70 years,
and history of varicose veins or venous insufficiency (signs
and symptoms of venous insufficiency existing previous to
the present acute event of DVT and/or previous treatment
or operations for varicosities).
Elastic compression therapy
All patients were initially bandaged for as long as it took
for the acute edema to resorb; new bandages were applied
three times a week for a median duration of 4 weeks.
Afterward, elastic compression stockings (ECS) were cus-
tom fitted, and patients were advised to wear these stock-
ings during the daytime. The stockings prescribed were
custom-made flat knitted stockings in two parts, one part
for the upper section of the leg from thigh to knee; the
other part was a knee-length stocking. A class III pressure
was standard. For elderly patients and patients with arterial
insufficiency, a class II stocking was stipulated (Mediven
550 [Medi Nederland BV, Breda, The Netherlands], ankle
pressure 40 mmHg [class III] or 30 mmHg [class II]). All
patients were advised to wear ECS for aminimal duration of
6 months after the acute event; the upper part of the
stocking was worn for no longer than 6 weeks.Assessments
Patients visited the outpatient clinic five times follow-
ing the acute event in the context of regular patient care.
The first visit took place within a month of the event, the
second visit at 3 months after the event, the third at 6
months, the fourth at 12 months, and the final visit was at
24 months after the event.
The first visit (2-3 weeks after the event) was scheduled
to assess the actual medical status (underlying malignan-
cies, excess bleeding risk, and risk of recurrent thrombosis).
A complete medical history was taken, and, in addition, a
full physical examination was performed. No assessment of
the affected leg was done at this first visit. Appraisal of
patients in the subacute stadium was not performed be-
cause of the expected presence of complaints related to the
acute phase of the event. The long-term effects of the
thrombosis were assessed during the extended follow-up
phase. All 125 patients were assessed at each of the four
follow-up visits following the initial screening visit for
compliance of elastic compression therapy. At each visit, a
clinical assessment of the affected leg was performed, and
signs and symptoms were scored using the Villalta score.14
In addition, duplex ultrasound analysis was performed once
(at 6 months after the event) during the entire follow-up
period in all patients.
Compression ultrasound assessment for residual
thrombosis. The initial diagnosis of DVT in the acute
phase was based on the result of a compression ultrasound
examination. Patients were re-examined 1 week before
planned cessation of anticoagulant treatment. In case resid-
ual thrombosis was present, treatment was prolonged in
order to diminish the risk of recurrence thrombosis.19-21
In all patients, results on re-examination were used as a
reference for future assessments in case of new complaints.
Assessment for signs of the PTS. The presence of
signs and symptoms indicative of PTS were scored accord-
ing to the Villalta score.14 This score contains five leg
symptoms and six objective signs. The leg symptoms in-
clude pain, cramps, heaviness, pruritis, and paresthesia. The
objective signs are pretibial edema, induration, new venous
ectasia, redness, and pain during calf compression. For all
items separately, a score of 0 to 3 could be assigned.
Patients were classified as having PTS if they had a score of
5 or more on two or more consecutive visits that were at
least 3 months apart. Venous ulceration was classified as
severe PTS regardless of the sum score total.14 The Villalta
score was preferred over other existing scores because of its
reported validity, sensitivity to change, and the relative
simplicity of the assessment.13,22 All patients were scored
by one physician during the entire follow-up period. This
physician was blinded to the results on duplex examination
but not to the actual status of compression therapy.
Duplex ultrasound assessment for venous insuffi-
ciency. All patients underwent duplex ultrasound assess-
ment in order to assess the presence of valvular insuffi-
ciency. Patients were examined in a reverse Trendelenburg
position on a tilting table in a 45° angle, the knees flexed
JOURNAL OF VASCULAR SURGERY
July 2010134 ten Cate-Hoek et aland with the feet resting on a foot support. Ten vein
segments were examined: the common femoral vein, the
superficial femoral vein (proximal and middle), the long
saphenous vein (proximal, middle, and distal), the popliteal
vein, the short saphenous vein, and the posterior and
anterior tibial veins. Reflux was measured in the longitudi-
nal plane. Proximal reflux was measured after the Valsalva
maneuver; distal reflux was measured by manual compres-
sion with sudden release. Normal duration of reflux in
proximal veins was less than 1.0 seconds, in a distal vein less
than 0.5 seconds. The scanner type used was Aloka SSD-
2000 [Aloka Co Ltd, Tokyo, Japan]; the probe type used
was a 7.5-MHZ linear transducer (for deep veins, a 3.5-
MHZ transducer was used) at a low-flow setting.
Patient management
Patients were allowed to discontinue elastic compres-
sion after the initial 6 months of therapy based on absence
of complaints (Villalta score 4) and absence of reflux on
duplex ultrasound testing. In case a PTS score of 5 was
present and/or if reflux was found, patients were advised to
continue compression therapy. Patients with objectively
confirmed reflux were allowed to stop compression therapy
if PTS scores were 4 on two consecutive visits. Patients
were diagnosed with PTS if they had a score of 5 on two
separate occasions at least 3 months apart.
Statistical Analysis
A sample size of 125 patients was considered sufficient,
based on the expected proportion of PTS in a population of
20% and the wish to exclude incidences up to 30% within a
95% confidence interval (CI), with a type I error of 0.05
and a type II error of 0.20.
Descriptive statistics were computed for baseline char-
acteristics, and cross-tabulations were made for PTS scores
per visit in relation to compression therapy.
Cumulative incidence of the PTS was estimated using
the Kaplan-Meier method; 95% CIs were calculated using
the standard error from the Kaplan-Meier estimation. Pa-
tients who were lost to follow-up or died were censored
after their last visit.
The association between PTS and clinical characteris-
tics was assessed for categorical variables using the Chi
square test. The variables analyzed were risk factors for
PTS, such as previous VTE, varicosities/venous insuffi-
ciency, obesity (cut-off body mass index, 26), age (cut-off,
70 years), gender, and duration of anticoagulant therapy,
residual thrombosis, reflux, and malignancy.
Adjusted hazard ratios for the effect of compression
therapy and their 95% CIs were calculated in the subse-
quent Cox regression analysis. All variables that generated a
P value of .05 in the univariate analysis were entered. All
analyses were performed with SPSS software package 13.0
for Windows (SPSS, Inc, Chicago, Ill).RESULTS
Patients
All 125 patients who visited the outpatient clinic for the
follow up of an acute DVT were included in the analysis.
The baseline characteristics for these patients are presented
in Table I.
Clinical events. Of the 125 patients who were fol-
lowed, complete follow-up was available for 102 patients.
Twenty-one patients (16.8%) were lost to follow-up in the
course of the 2-year follow-up period; two patients missed
the visit at 6 months, two additional patients missed the
12-month visit, and 17 only missed the final visit. Of these
21 patients, six patients had moved away, three could not
be followed due to substance abuse, three elderly patients
had transportation difficulties, and one patient suffered a
recurrent event and visited another hospital closer to her
home, while, for the remaining eight patients, no particular
reason for their lack of compliance could be identified.
Recurrence and death. Seven (5.6%) patients had an
objectively documented recurrent event within the follow-up
period. In addition, four (3.2%) patients died during the
follow-up period (two male, two female; three of them died
from metastasized malignancies (gastric, breast, lung), and
there was one case of sudden death at home.
Use of ECS
Some patients with Villalta scores 4 stopped wearing
compression stockings as early as 3months (7 of 91 patients
stopped on their own account); at 6 months 17% (16/94)
did not wear stockings, at 12 months 52% (41/85), and at
the 2-year follow-up visit 50% (41/82) did not have elastic
compression anymore (Table II, Fig 1). The seven patients
who stopped elastic compression on their own account
Table I. Baseline characteristics (N  125)
Characteristics N (%)
Men/women 51 (40.8)/74 (59.2)
Age in years 55.8 SD 1.48 (17-82)
Body mass index 26 65 (52)
Risk factors for VTE
Recent trauma 26 (20.8)
Recent surgery 26 (20.8)
Malignancy 5 (4.0)
Hormonal therapy 26 (20.8)
Pregnancy/puerpurum 1 (0.8)
Known thrombophilia at presentation 7 (5.6)
Varicosities/venous insuffficiency 14 (11.2)
Travel 10 hours 8 (6.4)
Previous VTE 27 (21.6)
Previous DVT 18 (14.4)
Previous ipsilateral DVT 9 (7.2)
Treatment duration
3 mo 25 (20)
6 mo 61 (48.8)
12 mo 16 (12.8)
24 mo or indefinite 21 (16.8)
DVT, Deep venous thrombosis; VTE, venous thromboembolism.developed no PTS. Of the patients who stopped compres-
), or
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restarted compression therapy because of worsening of
symptoms. These patients, although they did discontinue
compression therapy for quite some time, did not develop
PTS. Patients with Villalta scores 5 were all wearing
stockings for at least 6 months. Although not advised to
discontinue compression therapy, almost 40% (9/23) of
patients stopped wearing ECS. At 1 year, 60.9% (14/23)
were compliant with compression therapy; at the 2-year
follow-up visit, the compliance with therapy increased to
71.4% (10/14; Table II, Fig 1).
Duplex ultrasound testing
Duplex ultrasound testing for reflux was done in 101
Table II. Compression therapy during follow-up (N  12
Follow-up time Total N (%) compression
N (
0-3 mo 118 (99.2%) 28
4-6 mo 102 (86.4%) 24
7-12 mo 58 (53.7%) 14
13-24 mo 51 (53.1%) 10
*No score.
†Death.
#Lost to follow-up.
Score missing
3
6
17
BASELINE 125
28
28+ 0-
7 (2†,2#,3*)
1+    4? 2-
24
24+ 0-
17(3†,4# 10*)
3+    5? 9-
23 
14+         9-
6  (6*)
6+ 0-
29(4†,21#,4*)
0+   26? 3-
14
10+         4-
2+
1+
2+
10
3+ 6
1-,1+
7
*no score,† death, # lost to follow-up comp+=compression
unknown
1?
Score ≥ 5
16
13
12
Fig 1. The patient flow during follow-up. The patients
visit (3 months, 6 months, 12 months, and 24 months).
their original score (around 50% for those with a score 
arrows represent patients who have variable scores in bet
ECS () and patients without ECS (), and, in cases wh
cases, the Villalta score is missing (*), the patient died (†(80.8%) patients; a total of 74 (73.3%) had reflux either inthe superficial veins or in the deep venous system or both.
Thirty-one (31%) patients in whom reflux was objectively
confirmed in the deep vein system had repeated duplex
testing; no improvement was seen on repeated duplex
ultrasound testing over time. Of the 74 patients with reflux,
40 stopped wearing ECS in the course of the follow-up.
Thirty-one (77.5%) patients had a low PTS score, and nine
(22.5%) patients had a high PTS score.
Postthrombotic complaints and syndrome
Approximately 75% of all patients had a stable low score
(4), and approximately 15% had a stable high score (5).
Patients with severe PTS could already be identified at the
6-month visit (Table III, Fig 1). Only a very small propor-
pression
5
N (%) compression
score 4
N (%) score
unknown
(100%) 84/91 (92%) 6*
(100%) 78/94 (83%) 7 (2
†
,2#,3*)
(61%) 44/85 (52%) 17 (3
†
,4#,10*)
(71%) 41/82 (50%) 29 (4
†
,21#,4*)
Score ≤ 4
83
76
73
VISIT 2 
(3 months)
Comp+=118
Comp-=7
VISIT 3 
(6 months)
Comp+=103
Comp-=18
Comp?=4
VISIT 4
(12 months)
Comp+=61
Comp-=58
Comp?=6
VISIT 5
(24 months)
Comp+=51
Comp-=48
Comp?=26
p+
91
84+  7-
94 
78 +      16-
85  
44 +  1? 40-
82
41+        41-
2+
6+
6+,4-
8+
1-,8+ 
1?
-=no compression, ?= compression 
2+
ouped according to their Villalta score at each particular
old arrows depict the patient group who remains within
d around 85% for those with a score of 4). The small
visits. The numbers in the squares indicate patients with
t is unknown whether the patient had ECS, (?). In some
is lost to follow-up (#).5)
%) com
score
/28
/24
/23
/14 com
+
+,2-
+,2-
, comp
are gr
The b
5 an
ween
ere ition of patients (2%) worsened after 1 year. Overall, 37
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four visits. Based on the definition of the PTS, a score of5
on two separate occasions at least 3 months apart, only 24
(21.1%) of the 125 patients developed the syndrome in the
course of the 2-year follow-up period. Three of these patients
had severe PTS, one of whomwas diagnosed with and treated
for a venous ulcer at another hospital (Table III).
It is interesting to note that many patients with initial
scores above the threshold of 5 have lower scores at later
visits. Of the 29 patients that are not included in the final
assessment (21 who were lost to follow-up and eight who
had no Villalta score available for the last assessment), seven
(24 %) had a high score at the last available assessment, and
20 (69%) had a low score at the last available assessment; for
two (7%), no scores were available.
At 6 months after the event, 16 patients met the criteria
for the diagnosis of PTS. At 12 months, an additional four
patients were newly diagnosed with the syndrome, result-
ing in 20 symptomatic patients. After 24 months, a further
four patients developed PTS, leading to a total of 24
patients with symptomatic PTS at visit five. At 6 months,
the cumulative incidence of PTS was 13.3% (95% CI,
7.2-19.4), at 12months 17.0% (95%CI, 10.2-23.8), and at
the 24-month visit 21.1% (95% CI, 13.5-28.7) (Table IV).
Risk factors for the PTS
Of the tested variables, only reflux, varicosities/venous
insufficiency, and anticoagulant therapy with a duration of
3 months were significantly associated with PTS in the
univariate analysis. Duration of anticoagulant treatment of
3 months was negatively associated with PTS (odds ratio
[OR], 0.13; 95% CI, 0.02-0.84; P  .04). We found that
these patients more often lacked residual thrombosis:
17.4% vs 39.4% (OR, 0.32; 95% CI, 0.11-0.99; P .05). A
Table III. Villalta-Prandoni scores during follow-up
(N  125)
Follow-up time Score missing 5-14 15
3 mo 5 (4%) 25 (20%) 3 (2.4%)
6 mo 4 (3.2%) 23 (18.4%) 2 (1.6%)
12 mo 22 (17.6%) 22 (17.6%) 2 (1.6%)
24 mo 29 (23.2%) 13 (10.4%) 2 (1.6%)
Any time 38 (30.4%) 37 (29.6%) 3 (2.4%)
Table IV. Cumulative incidence of PTS during
follow-up (Kaplan-Meier estimates)
Follow-up
time
Number
at risk
N (95% CI) total
PTS (cum)
N (95% CI) Severe
PTS (cum)
3 mo 125 0 (–) 0 (–)
6 mo 125 16 (13.3  6.08) 2 (1.65%  2.27)
12 mo 94 20 (17.0  6.80) 3 (2.56%  2.86)
24 mo 79 24 (21.1  7.59) 3 (2.56%  2.86)
CI, Confidence interval; PTS, postthrombotic syndrome.positive association with PTS was observed for varicosities/venous insufficiency (OR, 7.5; 95%CI, 2.3-24.5; P .001)
and for combined reflux on duplex ultrasound (OR, 7.5;
95% CI, 1.19-45.8; P  .04); deep reflux alone was not
significantly associated with the outcome.
In the subsequent Cox regression analysis, however,
only the association with varicosities/venous insufficiency
remained significant (adjusted HR 3.2; 95% CI, 1.2-9.1;
P .028). Previous episodes of VTE, age, gender, residual
thrombosis, and longer duration of anticoagulant therapy,
malignancy, reflux, and obesity were not associated with
PTS.
Within the group of patients with varicosities/venous
insufficiency, 36% (5/14) had previously experienced
thrombosis compared with 19.8% (22/111) in the group
of patients with no previous episodes of DVT; this differ-
ence, however, was not significant.
DISCUSSION
We found that tailoring the duration of elastic com-
pression therapy based on the Villalta clinical score did not
have a negative impact on the subsequent incidence of PTS.
The outcome of our study showed that individualized
duration of compression therapy results in a cumulative
incidence of PTS over a 2-year period of 21.1% with a 95%
CI of 13.5 to 28.7. This compares well with results of active
arms in randomized studies.16,17 Similar results were found
in a recently published randomized but underpowered trial.
The incidence of PTS assessed according to the CEAP
classification was low in both the group that stopped at 6
months (20%) as well as in the group that continued
compression therapy for 24 months (13.1%).23
In our study, all patients were advised to wear ECS for
at least 6 months. The rationale for this was based both on
literature and on practical considerations. Literature sug-
gests that thrombus regression takes at least 6 months and
can benefit from compression therapy.7,24-27 Moreover,
the appraisal of patients in the subacute stadium of DVT is
difficult because of complaints related to the acute phase of
the thrombosis; it is therefore more desirable to assess
patients at a later moment in time.12
The presence of reflux as well as residual thrombosis is
believed to be important for venous hypertension, but no
consistent significant association with PTSwith any of these
two factors has been found in our patient population, nor
have these associations been established previously by
others.8,12 Although valvular reflux was found in approxi-
mately 70% of all patients, this did not significantly contrib-
ute to the outcome of PTS. Even in the presence of valvular
reflux, low scores on the Villalta score were common, and
discontinuation of elastic compression therapy in these
patients did not result in the development of PTS. We feel,
therefore, that this lack of association with the outcome of
PTS justifies the abolition of duplex reflux testing in future
assessment of patients for the individualization of elastic
compression therapy. Within the group of patients with
PTS, however, duplex testing will still retain its merits for
assessment of venous outflow resistance and diagnostic
work-up for surgical interventions.28-30
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for varicosities/venous insufficiency. Although part of our
patients with varicosities/venous insufficiency experienced
an earlier event, the percentage of previous events differed
not significantly from patients without varicosities/venous
insufficiency and is therefore not likely to explain the asso-
ciation to the outcome of PTS.
In the follow-up, four out of nine patients who had
previous thrombosis in the ipsilateral leg were eventually
diagnosed with PTS. This number of patients, however,
was not large enough to allow for definitive conclusions; no
significance was reached due to the small sample size. The
observation that 45% of patients with ipsilateral recurrence
developed PTS is in line with previous published findings
by other authors.16,31
Overall, we only identified a small group of patients with a
strong predisposition for PTS; they developed PTS regardless
of adequate elastic compression therapy. For the small group
of patients who develop PTS, more effective treatment op-
tions should therefore be established.29,30,32-34
Some weaknesses of our study have to be addressed.
First, our study was not a randomized trial but rather a
prospective management cohort study. The study had an
open character and was, as a result, prone to bias. There-
fore, in order to be able to draw firm conclusions on the
subject of individual tailoring of elastic compression ther-
apy, it would be desirable to perform an adequately pow-
ered, randomized clinical trial. Secondly, some known
strong predictors, such as recurrent thrombosis in the
ipsilateral leg, could not be confirmed because we did not
have a sufficient number of patients with previous ipsilateral
thrombosis of the leg in our study. A strong point of our
study is the inclusion of all consecutive patients with prox-
imal DVT and, therefore, the generalizability of the applied
management strategy.
In conclusion, our data suggest that after an acute event
of DVT, elastic compression therapy can be tailored indi-
vidually without an adverse effect on PTS incidence. Selec-
tion of patients for a shorter duration of elastic compression
therapy can be based on clinical scores only. A randomized
clinical trial is needed to confirm these data.
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